Nippon Shinyaku
Nippon Shinyaku Co Ltd is a Japanese pharmaceutical manufacturing enterprise developing prescription therapeutics and functional food ingredients. The company researches, produces, and commercializes pharmaceuticals for hematology, urology, rare genetic diseases, and musculoskeletal disorders, highlighted by Viltepso for Duchenne muscular dystrophy and Uptravi for pulmonary arterial hypertension. Main revenue drivers comprise global commercial sales of proprietary prescription pharmaceuticals, licensing milestone royalties, and functional food ingredient sales. Nippon Shinyaku serves urologists, hematologists, pediatric neurologists, hospital networks, and prescription pharmacies across Japan, North America, and Europe. The company holds a market-leading position in specialized treatments for rare neuromuscular diseases and urological conditions. Headquartered in Kyoto, Japan, Nippon Shinyaku Co Ltd is listed on the Tokyo Stock Exchange.
5 of the funds FundTelligence covers report a position in Nippon Shinyaku.
- Legal name
- Nippon Shinyaku Co Ltd
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 5
Funds holding Nippon Shinyaku
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.13 % (full portfolio disclosed, June 2026)
- Handelsbanken Infrastruktur och Beredskap — Handelsbanken · 0.07 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)